143 related articles for article (PubMed ID: 29526777)
21. Dual-specificity phosphatases are implicated in severe hyperplasia and lack of response to FGF23 of uremic parathyroid glands from rats.
Román-García P; Carrillo-López N; Naves-Díaz M; Rodríguez I; Ortiz A; Cannata-Andía JB
Endocrinology; 2012 Apr; 153(4):1627-37. PubMed ID: 22334717
[TBL] [Abstract][Full Text] [Related]
22. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
[TBL] [Abstract][Full Text] [Related]
23. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
Wetmore JB; Quarles LD
Nat Clin Pract Nephrol; 2009 Jan; 5(1):24-33. PubMed ID: 18957950
[TBL] [Abstract][Full Text] [Related]
24. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.
Arcidiacono MV; Sato T; Alvarez-Hernandez D; Yang J; Tokumoto M; Gonzalez-Suarez I; Lu Y; Tominaga Y; Cannata-Andia J; Slatopolsky E; Dusso AS
J Am Soc Nephrol; 2008 Feb; 19(2):310-20. PubMed ID: 18216322
[TBL] [Abstract][Full Text] [Related]
25. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
Toussaint ND; Damasiewicz MJ
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
[TBL] [Abstract][Full Text] [Related]
26. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.
Lopez I; Mendoza FJ; Aguilera-Tejero E; Perez J; Guerrero F; Martin D; Rodriguez M
Kidney Int; 2008 Feb; 73(3):300-7. PubMed ID: 18004298
[TBL] [Abstract][Full Text] [Related]
27. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
28. Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
Rottembourg J; Menegaux F
Clin Kidney J; 2019 Jun; 12(3):433-436. PubMed ID: 31198545
[TBL] [Abstract][Full Text] [Related]
29. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
Dusilová Sulková S
Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid growth and suppression in renal failure.
Lewin E; Huan J; Olgaard K
Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
32. Increased parathyroid expression of klotho in uremic rats.
Hofman-Bang J; Martuseviciene G; Santini MA; Olgaard K; Lewin E
Kidney Int; 2010 Dec; 78(11):1119-27. PubMed ID: 20631679
[TBL] [Abstract][Full Text] [Related]
33. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
[TBL] [Abstract][Full Text] [Related]
34. Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.
Wetmore JB; Quarles LD
Int J Nephrol Renovasc Dis; 2008; 1():5-17. PubMed ID: 21694914
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
36. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Uemura K; Kakuta T
Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
[TBL] [Abstract][Full Text] [Related]
37. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors.
Björklund P; Akerström G; Westin G
J Clin Endocrinol Metab; 2007 Jan; 92(1):338-44. PubMed ID: 17047023
[TBL] [Abstract][Full Text] [Related]
38. Abnormal expression and regulation of vitamin D receptor in experimental uremia.
Szabó A; Ritz E; Schmidt-Gayk H; Reichel H
Nephron; 1996; 73(4):619-28. PubMed ID: 8856261
[TBL] [Abstract][Full Text] [Related]
39. Cell biology of parathyroid hyperplasia in uremia.
Fukagawa M
Am J Med Sci; 1999 Jun; 317(6):377-82. PubMed ID: 10372837
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism.
Xiang Z; Wang M; Miao C; Jin D; Wang H
Front Pharmacol; 2022; 13():1020858. PubMed ID: 36267284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
